| Anticoagulation in patients with heart failure. | |
| | |
MedLine Citation:
|
PMID: 19689257 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The decision to anti-coagulate patients with heart failure (HF) is a difficult one, with limited data available to support clinical judgment. Thromboembolic complications, both arterial (stroke) and venous (deep vein thrombosis and pulmonary embolism), remain a significant cause of mortality and morbidity in this population. The pathophysiology of thrombogenesis in HF may be contextualized in the classic triad of stasis, endothelial dysfunction and hypercoagulability. Dilated cardiac chambers, reduced systolic function, and left ventricular aneurysm or thrombus have been suggested as potential contributing factors. HF is associated with activation of inflammatory and neuroendocrine pathways, leading to endothelial dysfunction and a prothrombotic state with dysregulated platelets and activation of the coagulation cascade. The epidemiology of thromboembolic events in HF is poorly defined. Most studies are retrospective and include patients with concurrent atrial fibrillation. The current body of health outcomes research is reviewed to identify the specific etiological factors, prevalence, and impact of thromboembolic events in this patient population. Conflicting analyses exist regarding the risks and benefits of prophylaxis in HF. The data surrounding several classes of therapeutic agents are synthesized. Recent clinical trials on anticoagulation and HF are reviewed, including WATCH, WASH, and WARCEF. The absence of compelling clinical trial data leaves many unanswered questions regarding systemic anticoagulation in patients with HF. |
| | |
Authors:
|
R Sacha Bhatia; Maral Ouzounian; Jack V Tu; Peter P Liu; Douglas S Lee |
Related Documents
:
|
12726807 - Virtual coronary cineangiography. 3665957 - Left ventricular thrombi after short-term high-dose anticoagulants in acute myocardial ... 17489767 - Acute heart failure after myocardial infarction. 12064567 - Clinical pharmacology of bivalirudin. 2208267 - Left main percutaneous transluminal coronary angioplasty with the autoperfusion cathete... 1869967 - Assessment of systolic thickening with thallium-201 ecg-gated single-photon emission co... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Cardiovascular & hematological agents in medicinal chemistry Volume: 7 ISSN: 1875-6182 ISO Abbreviation: - Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-08-19 Completed Date: 2009-10-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101266881 Medline TA: Cardiovasc Hematol Agents Med Chem Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 193-7 Citation Subset: IM |
Affiliation:
|
Institute for Clinical Evaluative Sciences, Toronto, Ontario, M4N 3M5 Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticoagulants
/
therapeutic use* Heart Failure / complications*, drug therapy*, epidemiology, physiopathology Humans Thromboembolism / epidemiology, physiopathology, prevention & control Thrombosis / epidemiology*, physiopathology, prevention & control* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The no-reflow phenomenon in the coronary circulation.
Next Document: Optimal management of hypertension in patients with ischemic heart disease.